Resolve Therapeutics LLC
Non-immunosuppressive biologics for autoimmune diseases
- Sector
- Biotech
- Headquarters
- Seattle, WA
- Founded
- 2010
- Latest Form D
- $5.8M, Jan 2013
- Total capital
- $8.9M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $8.9M
- 3 Form D · last Jan 2013
- 165 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 21 pending · first 2021
- Rank in peer group#339 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$5.8M
- Private capital raisedForm D · SEC · 2nd filing$1.1M
- Private capital raisedForm D · SEC · 1st filing$2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#339 · top 23%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- James PosadaExecutive Officer, PromoterNamed in SEC Form D filings
- Peter KienerExecutive OfficerNamed in SEC Form D filings
- Somu SubramaniamExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 24- PendingNucleic Acid Molecules Encoding Nuclease-albumin Fusion ProteinsUSPTOApplication 18927271
- PendingOptimized Binuclease Fusions And MethodsUSPTOApplication 18768643
- PendingOptimized Binuclease Fusions And MethodsUSPTOApplication 18768662
Show all 24 patent records
- Nucleic Acid Molecules Encoding Nuclease-albumin Fusion ProteinsApr 24, 2025 · Application 18927271Pending
- Optimized Binuclease Fusions And MethodsJan 2, 2025 · Application 18768643Pending
- Optimized Binuclease Fusions And MethodsJan 2, 2025 · Application 18768662Pending
- Nucleic Acid Molecules Encoding Nuclease-albumin Fusion ProteinsDec 10, 2024 · US 12,163,165Granted
- Optimized Binuclease Fusions And MethodsSep 3, 2024 · US 12,077,790Granted
- Treatment Of Sjogren's Syndrome With Nuclease Fusion ProteinsNov 9, 2023 · Application 18012459Pending
- Treatment Of Sjogren's Disease With Nuclease Fusion ProteinsMar 24, 2022 · Application 17420365Pending
- Therapeutic Nuclease-albumin Fusions And MethodsApr 27, 2021 · US 10,988,745Granted
- Optimized Binuclease Fusions And MethodsAug 8, 2019 · Application 16313656Pending
- Therapeutic Nuclease-albumin Fusions And MethodsApplication PCTUS2014063572Pending
- Therapeutic Nuclease-transferrin Fusions And MethodsApplication 62073857Pending
- Therapeutic Nuclease Molecules With Altered Glycosylation And MethodsApplication PCTUS2014063587Pending
- Therapeutic Nuclease-albumin Fusions And MethodsApplication 61898393Pending
- Therapeutic Nuclease Molecules With Altered Glycosylation And MethodsApplication 61898370Pending
- Treatment Of Symptoms Associated With Sars-cov Viral Infection Or A Prior Sars-cov Viral Infection With Nuclease AgentsApplication PCTUS2025010402Pending
- Therapeutic Nuclease Molecules With Altered Glycosylation And MethodsApplication 61898384Pending
- TREATMENT OF SYMPTOMS ASSOCIATED WITH SARS-CoV VIRAL INFECTION OR A PRIOR SARS-CoV VIRAL INFECTION WITH NUCLEASE AGENTSApplication 63618266Pending
- Treatment Of Sjogren's Syndrome With Nuclease Fusion ProtiensApplication PCTUS2021039683Pending
- Treatment Of Sjogren's Syndrome With Nuclease Fusion ProteinsApplication 63045705Pending
- Treatment Of Sjogren's Disease With Nuclease Fusion ProteinsApplication PCTUS2020012258Pending
- Treatment Of Sjogren's Disease With Nuclease Fusion ProteinsApplication 62788730Pending
- Optimized Binuclease Fusions And MethodsApplication PCTUS2017040267Pending
- Optimized Binuclease Fusions And MethodsApplication 62357756Pending
- Therapeutic Nuclease-transferrin Fusions And MehtodsApplication PCTUS2015058039Pending
Related companies, and why
- Chemomab Therapeutics Ltd.Similar federal contract value in Biotech · null in contracts
- Lumena Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Mosaic Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- Strategic Science & Technologies LLCSimilar federal contract value in Biotech · null in contracts
- Stem Cell Reserve, LPSimilar federal contract value in Biotech · null in contracts
- Disket IncSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .